Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies. Learn why RIGL stock is a Buy.

Cancer researchers are making strides in efforts to use genetic profiling to develop a more precise understanding of the response to treatment of acute ...

The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance ...

Fred Hutch Cancer Center hematologists took center stage at the 2026 Tandem Meetings, a multidisciplinary meeting of experts in the field of blood stem cell transplantation, held in Salt Lake City ...

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.

Acute myeloid leukemia, often called AML, is one of the most aggressive forms of blood cancer. It develops in the bone marrow, the soft tissue inside bones where blood cells are made. In healthy ...

An investigational approach to diagnosis of prostate cancer uses sound waves to extract "bubbles of information" from cells. ...

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were poorly differentiated.

KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions –– Market feedback emphasizes differentiated ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...